We are a leading clinical-stage gene therapy company focused on developing and commercializing novel, one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness.
PATIENTS & CAREGIVERSCLINICAL TRIALSAREAS OF FOCUS
Our mission is to maintain and restore sight in patients with inherited retinal diseases.
Our patients are at the forefront of everything we do. They inspire us to work hard every day in an effort to bring sight-saving therapies to people with blinding eye diseases.
OUR CLINICAL PROGRAMS
We are evaluating NSR-REP1, a gene therapy for the treatment of choroideremia (CHM), a rare, degenerative, genetic retinal disorder that presents itself in childhood and generally leads to vision loss in early adulthood and total blindness thereafter.
X-LINKED RETINITIS PIGMENTOSA
Our NSR-RPGR gene therapy is being evaluated for the treatment of X-linked retinitis pigmentosa (XLRP), an inherited X-linked recessive retinal disease that causes night blindness during childhood, followed by a narrowing of peripheral vision and progressive loss of central vision and eventually legal or total blindness.
|NIGHTSTAR THERAPEUTICS PLC||2017-09-15 - 2019-06-11|
|NIGHTSTAR THERAPEUTICS LIMITED||2017-07-06 - 2017-09-15|
- 4573 Biotechnology
- Company Number
- Private Limited Company
- Company Age
- 2 years
- July 6, 2017
- Nature of Business
- 64209 - Activities of other holding companies n.e.c.
- Year End
- December 31
- Accounts Due
- September 30, 2020
- Latest Accounts
- December 31, 2018
Biogen Announces Agreement to Acquire Nightstar Therapeutics to ...Source:investors.biogen.com
Mar 4, 2019 ... Biogen to acquire Nightstar Therapeutics for $25.50 per share. Nightstar Therapeutics is a gene therapy company focused on developing novel ...
NIGHTSTAR THERAPEUTICS | LinkedInSource:www.linkedin.com
See who you know at NIGHTSTAR THERAPEUTICS , leverage your professional network, and get hired. ... Head of Clinical Assays at PsiOxus Therapeutics Ltd.
Biogen closes $800m Nightstar Therapeutics acquisitionSource:www.pharmaceutical-technology.com
Jun 10, 2019 ... Biogen has closed the acquisition of Nightstar Therapeutics for around $800m, marking its entry into ophthalmology therapeutic area.
Nightstar Therapeutics plc reaches agreement to be acquired by ...Source:www.globenewswire.com
Mar 4, 2019 ... NIGHTSTAR THERAPEUTICS PLC ("NIGHTSTAR") BY TUNGSTEN BIDCO LIMITED ("BIDCO") a wholly-owned subsidiary of BIOGEN ...
Why Nightstar Therapeutics Stock Skyrocketed 71% in March | The ...Source:www.fool.com
Apr 3, 2019 ... Shares of Nightstar Therapeutics (NASDAQ:NITE), a U.K-based clinical-stage gene therapy company, soared 71.2% in March, according to ...
Nightstar Therapeutics PLC Completion of Acquisition by Biogen ...Source:www.globenewswire.com
Jun 7, 2019 ... June 07, 2019 05:44 ET | Source: Nightstar Therapeutics ... be issued share capital of Nightstar has been acquired by Tungsten Bidco Limited, ...